{"url_path":"/sec/sgmt/8-k/2026-07-21/item-7-01","section_key":"item-7-01","section_title":"Item 7.01 Regulation FD Disclosure.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-21","source_url":"https://www.sec.gov/Archives/edgar/data/1400118/0001193125-26-309334-index.html","accession_number":"0001193125-26-309334","cik":"0001400118","ticker":"SGMT","issuer_name":"Sagimet Biosciences Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1400118/0001193125-26-309334-index.html","primary_entity_key":"0001400118","primary_entity_name":"Sagimet Biosciences Inc."},"word_count":144,"has_tables":true,"body_markdown":"Item 7.01\n\nRegulation FD Disclosure.\n\nOn July 20, 2026, Sagimet Biosciences Inc. (the “Company”) updated information reflected in a slide presentation, which is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. Representatives of the Company will use the updated presentation in various meetings with investors from time to time.\n\nThe information in Item 7.01 of this Current Report on Form 8-K, including the information set forth in Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor shall Exhibit 99.1 furnished herewith be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing."}